 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 11–14% |
| Excretion | 83% via urine within 96 h |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.167.719 |
| Chemical and physical data | |
| Formula | C13H20N2O2 |
| Molar mass | 236.315 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Levodropropizine is acough suppressant. It is thelevo isomer ofdropropizine. It acts as a peripheral antitussive, with no action in thecentral nervous system.[1] It does not causeside effects such asconstipation orrespiratory depression which can be produced byopioid antitussives such ascodeine and its derivatives.
In September 2021, Korea United Pharm file lawsuits against 15 drug manufacturers aspatent infringement protection for its 2017 registeredantitussive drug Levotics CR Tab. (levodropropizine). The cases are anchored on violation of its patent for "Method for Preparing Sustained-Release Tablets Containing Levodropropizine."[2] In September 2023, KUP signed a five-year $52.1 million contract with MCQ, a Thai-based pharmaceutical company, for supply of itsmucoactive drug, Levotics CR Tab (levodropropizine).[3]
 | Thisdrug article relating to therespiratory system is astub. You can help Wikipedia byadding missing information. |